Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Traws Pharma (TRAW) Receivables - Net (2016 - 2025)

Historic Receivables - Net for Traws Pharma (TRAW) over the last 12 years, with Q3 2025 value amounting to $2.0 million.

  • Traws Pharma's Receivables - Net fell 612.92% to $2.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.0 million, marking a year-over-year decrease of 612.92%. This contributed to the annual value of $1.8 million for FY2024, which is 970555.56% up from last year.
  • As of Q3 2025, Traws Pharma's Receivables - Net stood at $2.0 million, which was down 612.92% from $1.3 million recorded in Q2 2025.
  • Traws Pharma's 5-year Receivables - Net high stood at $2.1 million for Q3 2024, and its period low was $17000.0 during Q1 2023.
  • Its 5-year average for Receivables - Net is $483894.7, with a median of $28000.0 in 2021.
  • In the last 5 years, Traws Pharma's Receivables - Net tumbled by 3928.57% in 2023 and then skyrocketed by 1168333.33% in 2024.
  • Quarter analysis of 5 years shows Traws Pharma's Receivables - Net stood at $28000.0 in 2021, then rose by 3.57% to $29000.0 in 2022, then plummeted by 37.93% to $18000.0 in 2023, then soared by 9705.56% to $1.8 million in 2024, then rose by 12.8% to $2.0 million in 2025.
  • Its Receivables - Net stands at $2.0 million for Q3 2025, versus $1.3 million for Q2 2025 and $1.7 million for Q1 2025.